

May 23, 2024

Q4FY24 Result Update

☒ Change in Estimates | ■ Target | ■ Reco

Change in Estimates

Rating	Current		Previous	
	FY25E	FY26E	FY25E	FY26E
Target Price	SELL 206	SELL 206		
Sales (Rs. m)	31,972	36,269	32,475	36,118
% Chng.	(1.6)	0.4		
EBITDA (Rs. m)	3,173	3,714	3,377	4,012
% Chng.	(6.1)	(7.4)		
EPS (Rs.)	6.1	7.3	6.6	8.6
% Chng.	(7.2)	(14.7)		

Key Financials - Consolidated

Y/e Mar	FY23	FY24	FY25E	FY26E
Sales (Rs. m)	27,912	28,650	31,972	36,269
EBITDA (Rs. m)	2,391	2,557	3,173	3,714
Margin (%)	8.6	8.9	9.9	10.2
PAT (Rs. m)	1,246	1,205	1,609	1,935
EPS (Rs.)	4.7	4.4	6.1	7.3
Gr. (%)	(51.9)	(7.0)	39.6	20.3
DPS (Rs.)	0.5	0.4	0.6	0.7
Yield (%)	0.2	0.2	0.2	0.3
RoE (%)	9.2	7.5	9.3	11.0
RoCE (%)	10.3	8.0	9.6	10.2
EV/Sales (x)	2.5	2.4	2.1	1.8
EV/EBITDA (x)	29.5	26.5	21.3	18.0
PE (x)	54.7	58.8	42.1	35.0
P/BV (x)	4.8	3.9	4.1	3.7

Key Data	LAXR.BO LXCHEM IN
52-W High / Low	Rs.321 / Rs.222
Sensex / Nifty	75,418 / 22,968
Market Cap	Rs.71bn/ \$ 850m
Shares Outstanding	276m
3M Avg. Daily Value	Rs.325.46m

Shareholding Pattern (%)

Promoter's	69.72
Foreign	0.85
Domestic Institution	3.44
Public & Others	26.00
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	2.9	(4.5)	0.1
Relative	0.6	(16.4)	(17.8)

Swarnendu Bhushan

swarnendubhushan@plindia.com | 91-22-66322260

Saurabh Ahire

saurabhahire@plindia.com |

Laxmi Organic Industries (LXCHEM IN)

Rating: SELL | CMP: Rs257 | TP: Rs206

Project ramp ups to take time

Quick Pointers:

- Approval received for Rs 7.1bn Dahej project, construction to start soon
- Merger of fully owned subsidiary Yellowstone Fine Chemicals Pvt. Ltd., Lote to Laxmi Organics Limited approved by board

Laxmi Organic Industries (LXCHEM) reported a topline of Rs 7.9bn, marking an 8% YoY growth driven by a 14% increase in volume. EBITDAM improved by 300bps YoY due to lower overheads. However, the contribution from exports decreased by 500 basis points YoY, primarily due to weak global demand in the pharma and agro sectors. The Company's Fluoro intermediate plant with a peak revenue capacity of Rs 2bn is ready, but it will take another three years to ramp up. Additionally, the Dahej project has received its first approval, and construction at the site is expected to commence soon. As a result of the ramp ups and concerning macro environment of demand, we remain cautious on the stock. The stock currently trades at 35x FY26 EPS. Using SOTP, we value it at Rs 206, implying ~20% downside from here. We recommend a Sell rating on the stock.

Revenue growth driven by both Essentials and Specialties segment: Consolidated revenue stood at Rs 7.9bn (8% YoY/ 14.2% QoQ) (Ple: Rs 7.11bn, Consensus: Rs 7.12bn). increased primarily due to 16% YoY growth in Essentials segment and +12% YoY growth in Specialties segment. For FY24, topline improved by 2.7% to Rs 28.7bn (Essentials Rev: Rs 19.5bn; Specialties Rev: Rs 8.4bn) from Rs 27.9bn in FY23, while EBITDA margin declined to 33% from 34%.

Improved product mix in Specialties led to increase in EBITDA: EBITDA stood at Rs 900mn increased 48% YoY/ 74.5% QoQ, EBITDA margin came at 11.4% (vs 8.3% in Q4FY23 and 7.4% in Q3FY24). FY24 EBITDA stood at Rs 2.57bn, 5.4% increase YoY. PAT was at Rs 443mn increased by 82% YoY/ 62.6% QoQ. FY24 PAT was at Rs 1.2bn, 3.3% decline YoY, due to higher charge of depreciation on account of capitalization of Lote assets.


Concill key takeaways: (1) Demand in North America better than other parts of the world, domestic demand is also high (2) **Key Raw material update:** Acetic Acid: Price at \$430-\$450 mt and Ethanol: Price at \$720-\$750 mt, expected to continue in Q1FY25 (3) **Fluro intermediate project:** First sales happened in FY24, ramp up to deliver sales in FY25, first product successfully qualified, signed a contract with a MNC for delivery in FY25 (4) **Dahej Project:** Received first approval, construction to begin shortly (5) Fluoro chemical plant ramp up will take 3 yrs to ramp up and peak revenue is expected to be Rs 2bn (6) Export & Import mix – 70%-30% (7) For Ethyl Acetate business the company expects 3-3.5x asset turnover and 8%-10% EBITDA margin (8) Volumes for Q4FY24 were up by 14% on QoQ and 23% YoY, for FY24 volumes were up by 20% (9) Merger of fully owned subsidiary Yellowstone Fine Chemicals Pvt. Ltd., Lote to Laxmi Organics Limited approved by board

Exhibit 1: Q4FY24 Result Overview – Consolidated (Rs mn)

Y/e March	Q4FY24	Q4FY23	YoY gr. (%)	Q4FY24E	% Var.	Q3FY24	QoQ gr. (%)	FY24	FY23	YoY gr. (%)
Net Sales	7,921	7,332	8.0	7,112	11.4	6,936	14.2	28,650	27,912	2.6
Gross Profit	2,881	2,452	17.5	2,227	29.3	2,124	35.7	9,403	9,360	0.5
Margin (%)	36.4	33.4		31.3		30.6		32.8	33.5	
EBITDA	900	607	48.2	599	50.1	516	74.5	2,557	2,391	7.0
Margin (%)	11.4	8.3		8.4		7.4		8.9	8.6	
Other Income	79.0	38.4	105.8	42.0	88.2	60.4	30.9	282.3	175.3	61.1
Depreciation	306	230	32.6	277	10.2	275	11.0	1,066	724	47.2
EBIT	594	377	57.8	322	84.5	240	147.3	1,491	1,667	(10.5)
Interest	-6.3	-12	(48.8)	7.8	(181.3)	5	-221.5	65	113	(41.8)
PBT before exceptional items	680	427	59.0	356	90.8	296	130.0	1,708	1,729	(1.2)
Total Tax	237	185	28.3	53	349.8	24	902.6	503	483	4.1
ETR (%)	34.8	34.8		14.8				29.4	27.9	
Adj. PAT	443	243	82.1	304	45.9	272	62.6	1,205	1,246	(3.3)


Source: Company, PL

Exhibit 2: Revenue improved on increase in volumes




Source: Company, PL

Exhibit 3: EBITDA margin improved due to lower overheads




Source: Company, PL

Exhibit 4: Fluorochemicals to start contributing from FY25



Source: Company, PL

Exhibit 5: Return ratios to be around 9-11%



Source: Company, PL

Exhibit 6: Valuation – SOTP based TP at Rs 221; Maintain Sell rating**SOTP**

Enterprise Value (Rs mn)	EV/EBITDA (x)	Per Share
Specialty Intermediates	16	161
Fluorochemicals	18	10
Acetyl Intermediates	10	34
Enterprise Value		206
Less: Net Debt and Investments		-0.5
Fair Value / Target Price (Rs)		206

Source: PL

Financials

Income Statement (Rs m)

Y/e Mar	FY23	FY24	FY25E	FY26E
Net Revenues	27,912	28,650	31,972	36,269
YoY gr. (%)	(9.5)	2.6	11.6	13.4
Cost of Goods Sold	18,552	19,248	21,189	23,947
Gross Profit	9,360	9,403	10,782	12,322
Margin (%)	33.5	32.8	33.7	34.0
Employee Cost	1,159	1,479	1,700	1,904
Other Expenses	5,810	5,367	5,909	6,704
EBITDA	2,391	2,557	3,173	3,714
YoY gr. (%)	(35.0)	7.0	24.1	17.1
Margin (%)	8.6	8.9	9.9	10.2
Depreciation and Amortization	724	1,066	1,276	1,613
EBIT	1,667	1,491	1,897	2,101
Margin (%)	6.0	5.2	5.9	5.8
Net Interest	113	65	58	74
Other Income	175	282	311	559
Profit Before Tax	1,729	1,708	2,150	2,586
Margin (%)	6.2	6.0	6.7	7.1
Total Tax	483	503	541	651
Effective tax rate (%)	27.9	29.4	25.2	25.2
Profit after tax	1,246	1,205	1,609	1,935
Minority interest	0	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	1,246	1,205	1,609	1,935
YoY gr. (%)	(51.6)	(3.3)	33.5	20.3
Margin (%)	4.5	4.2	5.0	5.3
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	1,246	1,205	1,609	1,935
YoY gr. (%)	(51.6)	(3.3)	33.5	20.3
Margin (%)	4.5	4.2	5.0	5.3
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	1,246	1,205	1,609	1,935
Equity Shares O/s (m)	265	276	264	264
EPS (Rs)	4.7	4.4	6.1	7.3

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

Y/e Mar	FY23	FY24	FY25E	FY26E
Non-Current Assets				
Gross Block	10,234	12,941	18,883	21,383
Tangibles	10,208	12,916	18,857	21,357
Intangibles	26	26	26	26
Acc: Dep / Amortization	3,121	4,187	5,462	7,076
Tangibles	3,103	4,169	5,444	7,058
Intangibles	18	18	18	18
Net fixed assets	7,113	8,755	13,421	14,307
Tangibles	7,105	8,747	13,413	14,300
Intangibles	8	8	8	8
Capital Work In Progress	4,471	4,442	1,000	1,000
Goodwill	33	33	33	33
Non-Current Investments	131	99	99	99
Net Deferred tax assets	(272)	(283)	(283)	(283)
Other Non-Current Assets	207	172	172	172
Current Assets				
Investments	200	1,231	1,231	1,231
Inventories	2,942	2,833	3,329	3,776
Trade receivables	5,702	5,834	6,511	7,386
Cash & Bank Balance	1,309	3,171	2,232	2,148
Other Current Assets	1,301	1,262	1,409	1,598
Total Assets	24,122	28,272	29,927	32,307
Equity				
Equity Share Capital	530	552	527	527
Other Equity	13,587	17,425	16,133	17,875
Total Networth	14,118	17,976	16,661	18,402
Non-Current Liabilities				
Long Term borrowings	1,303	972	2,672	2,700
Provisions	41	61	61	61
Other non current liabilities	81	64	64	64
Current Liabilities				
ST Debt / Current of LT Debt	2,666	385	667	-
Trade payables	4,663	7,621	8,505	9,648
Other current liabilities	972	905	1,010	1,145
Total Equity & Liabilities	24,122	28,272	29,927	32,307

Source: Company Data, PL Research

Cash Flow (Rs m)

Y/e Mar	FY23	FY24	FY25E	FY26E
PBT	1,729	1,708	2,150	2,586
Add. Depreciation	724	1,066	1,276	1,613
Add. Interest	107	63	58	74
Less Financial Other Income	175	282	311	559
Add. Other	64	63	(311)	(559)
Op. profit before WC changes	2,625	2,900	3,173	3,714
Net Changes-WC	(133)	3,086	(386)	(307)
Direct tax	(501)	(371)	(535)	(643)
Net cash from Op. activities	1,991	5,616	2,251	2,764
Capital expenditures	(4,757)	(2,475)	(2,500)	(2,500)
Interest / Dividend Income	84	128	311	559
Others	832	(2,548)	(2,740)	-
Net Cash from Invt. activities	(3,841)	(4,895)	(4,929)	(1,941)
Issue of share cap. / premium	94	2,676	(24)	-
Debt changes	2,632	(2,612)	1,982	(639)
Dividend paid	(186)	(133)	(161)	(193)
Interest paid	(194)	(217)	(58)	(74)
Others	(127)	(27)	-	-
Net cash from Fin. activities	2,219	(314)	1,739	(907)
Net change in cash	369	407	(939)	(84)
Free Cash Flow	(2,768)	3,139	(249)	264

Source: Company Data, PL Research

Key Financial Metrics

Y/e Mar	FY23	FY24	FY25E	FY26E
Per Share(Rs)				
EPS	4.7	4.4	6.1	7.3
CEPS	7.4	8.2	10.9	13.5
BVPS	53.2	65.2	63.2	69.8
FCF	(10.4)	11.4	(0.9)	1.0
DPS	0.5	0.4	0.6	0.7
Return Ratio(%)				
RoCE	10.3	8.0	9.6	10.2
ROIC	8.3	6.7	9.0	9.2
RoE	9.2	7.5	9.3	11.0
Balance Sheet				
Net Debt : Equity (x)	0.2	(0.2)	0.0	0.0
Net Working Capital (Days)	52	13	15	15
Valuation(x)				
PER	54.7	58.8	42.1	35.0
P/B	4.8	3.9	4.1	3.7
P/CEPS	34.6	31.2	23.5	19.1
EV/EBITDA	29.5	26.5	21.3	18.0
EV/Sales	2.5	2.4	2.1	1.8
Dividend Yield (%)	0.2	0.2	0.2	0.3

Source: Company Data, PL Research


Quarterly Financials (Rs m)

Y/e Mar	Q1FY24	Q2FY24	Q3FY24	Q4FY24
Net Revenue	7,336	6,523	6,936	7,921
YoY gr. (%)	(3.0)	-	6.0	8.0
Raw Material Expenses	4,779	4,617	4,812	5,040
Gross Profit	2,557	1,906	2,124	2,881
Margin (%)	34.9	29.2	30.6	36.4
EBITDA	773	389	516	900
YoY gr. (%)	(23.0)	36.0	(5.9)	48.2
Margin (%)	10.5	6.0	7.4	11.4
Depreciation / Depletion	210	275	275	306
EBIT	564	114	240	594
Margin (%)	7.7	1.7	3.5	7.5
Net Interest	46	21	5	(6)
Other Income	40	82	60	79
Profit before Tax	557	175	296	680
Margin (%)	7.6	2.7	4.3	8.6
Total Tax	174	68	24	237
Effective tax rate (%)	31.2	38.9	8.0	34.8
Profit after Tax	383	107	272	443
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	384	108	272	443
YoY gr. (%)	(40.4)	25.0	(0.1)	82.1
Margin (%)	5.2	1.6	3.9	5.6
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	384	108	272	443
YoY gr. (%)	(40.4)	25.0	(0.1)	82.1
Margin (%)	5.2	1.6	3.9	5.6
Other Comprehensive Income	2	3	-	-
Total Comprehensive Income	386	111	273	443
Avg. Shares O/s (m)	265	265	265	265
EPS (Rs)	1.4	0.4	1.0	1.7

Source: Company Data, PL Research

Price Chart

Recommendation History



No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	09-Apr-24	Sell	206	251
2	25-Jan-24	Sell	221	271
3	08-Jan-24	Reduce	267	289
4	30-Oct-23	Reduce	220	254
5	09-Oct-23	Reduce	252	280

Analyst Coverage Universe

Sr. No.	CompanyName	Rating	TP (Rs)	Share Price (Rs)
1	Aarti Industries	Reduce	595	669
2	Ashok Leyland	BUY	210	176
3	Bajaj Auto	Sell	7,267	9,021
4	Bharat Forge	BUY	1,615	1,405
5	Bharat Petroleum Corporation	Reduce	547	619
6	Bharti Airtel	Accumulate	1,373	1,310
7	CEAT	BUY	3,017	2,545
8	Clean Science and Technology	Hold	1,383	1,328
9	Deepak Nitrite	Reduce	2,268	2,464
10	Divgi Torqtransfer Systems	BUY	1,135	843
11	Eicher Motors	BUY	5,335	4,658
12	Endurance Technologies	Accumulate	2,346	2,168
13	Exide Industries	Accumulate	495	472
14	Fine Organic Industries	Accumulate	4,779	4,287
15	GAIL (India)	Sell	163	209
16	Gujarat Fluorochemicals	Reduce	3,120	3,638
17	Gujarat Gas	Accumulate	589	553
18	Gujarat State Petronet	BUY	400	294
19	Hero Motocorp	BUY	5,629	4,614
20	Hindustan Petroleum Corporation	Sell	420	501
21	Indian Oil Corporation	Reduce	151	169
22	Indraprastha Gas	Sell	368	452
23	Jubilant Ingrevia	Hold	526	512
24	Laxmi Organic Industries	Sell	206	251
25	Mahanagar Gas	Sell	1,116	1,300
26	Mahindra & Mahindra	BUY	2,716	2,372
27	Mangalore Refinery & Petrochemicals	Sell	142	233
28	Maruti Suzuki	BUY	14,432	12,703
29	Navin Fluorine International	Accumulate	3,621	3,377

PL's Recommendation Nomenclature (Absolute Performance)

Buy	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

ANALYST CERTIFICATION

(Indian Clients)

We/I, Mr. Swarnendu Bhushan- IIT, MBA Finance, Mr. Saurabh Ahire- MBA, Passed CFA Level II Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Swarnendu Bhushan- IIT, MBA Finance, Mr. Saurabh Ahire- MBA, Passed CFA Level II Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209
www.plindia.com